Avidity Biosciences, Inc. (RNA) analyst actions
Rating and price-target actions on RNA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RNA overview →
2 measured RNA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD | Press release | -5.71% | -14.05% | |
| Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy | Press release | +0.89% | -1.88% |
Keep exploring
More RNA: earnings → · SEC filings → · RNA overview →